Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,264 public trials 216 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Infirmary Cancer Care ( Site 0157) Mobile, Alabama, United States
  • Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona, United States
  • Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona, United States
  • City of Hope - Phoenix ( Site 0202) Goodyear, Arizona, United States
View all 146 locations
View Trial Details
Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Colorado Blood Cancer Institute ( Site 7000) Denver, Colorado, United States
  • SCRI Oncology Partners ( Site 0100) Nashville, Tennessee, United States
  • Instituto Alexander Fleming ( Site 1404) Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) Rosario, Santa Fe Province, Argentina
View all 41 locations
View Trial Details
Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
View all 190 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 278 locations
View Trial Details
Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812

Conditions
Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Immune System Diseases, +23 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
View all 104 locations
View Trial Details
Recruiting

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

NCT06220032

Conditions
Cardiotoxicity, Cardiovascular Diseases, Chemically-Induced Disorders, +22 more
Locations
  • NL-Den Bosch-JBZ 's-Hertogenbosch, Netherlands
  • NL-Almelo-ZGTALMELO Almelo, Netherlands
  • NL-Amstelveen-AMSTELLAND Amstelveen, Netherlands
  • NL-Apeldoorn-GELREAPELDOORN Apeldoorn, Netherlands
View all 25 locations
View Trial Details
Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 51 locations
View Trial Details
Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Mayo Clinic - Scottsdale Scottsdale, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California, Los Angeles (UCLA) - Medical Center Los Angeles, California, United States
  • University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
View all 46 locations
View Trial Details

Related conditions